Phase 1 Pulmonary Hypertension Trial, Recruiting NCT06899815 Sponsor: Beijing Continent Pharmaceutical Co, Ltd. Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Phase 1 Pulmonary Hypertension Trial, Recruiting

NCT06899815
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a healthy volunteer (the trial aims for an equal number of men and women, and if you drop out, you would be replaced by someone of the same sex)
  • You are between 18 and 45 years old
  • If you are male, you weigh at least 50kg; if you are female, you weigh at least 45kg; and your BMI (a measure of body weight relative to height) is between 19 and 26
  • You have passed a full health check-up covering things like blood tests, urine tests, heart tracing (ECG), liver and kidney function, checks for infections like hepatitis B, hepatitis C, HIV and syphilis, a chest X-ray, an abdominal scan, and tests for nicotine, drugs, and alcohol — with no significant health concerns found
  • You fully understand what the trial involves, including its possible benefits and risks, and are willing to sign a consent form and follow all study requirements

Who may not be able to join:

  • You have taken part in another clinical trial within the last 3 months
  • Your blood test results show that your liver function markers (ALT, AST, or bilirubin) are above the normal range
  • You have an existing liver condition, such as chronic hepatitis B or C, alcoholic liver disease, significant fatty liver disease, or cirrhosis (confirm with trial site)
  • You have any condition affecting your heart, liver, kidneys, hormones, digestion, immune system, lungs, nerves, or mental health — including cardiovascular disease, bowel conditions that affect how you absorb medicines, active bleeding (such as stomach ulcers), epilepsy, severe allergic skin or breathing conditions, or active tuberculosis
  • You have a history of allergies to any medicines, foods, or skin-related allergens
  • You have taken any medicines in the 28 days before the trial that are known to affect how the liver processes drugs — including certain antibiotics, antifungals, anti-seizure medicines, steroids, or other specific drugs (confirm the full list with the trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 027-85726085

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Beijing Continent Pharmaceutical Co, Ltd.
Registry
ClinicalTrials.gov
Start date
15 May 2025
Est. completion
1 July 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Single dose:PK parameters: Cmax; Single dose:PK parameters: Tmax; Single dose:PK parameters: AUC0-t; Single dose:PK parameters: AUC0-∞; Single dose:PK parameters: t1/2; Single dose:PK parameters: λz; Single dose:PK parameters: Vz/F; Single dose:PK parameters: CL/F; Single dose:PK parameters: AUC_%Extrap; Single dose:PK parameters: MRT; Single dose:PK parameters: Ae_u (t1-t2); Single dose:PK parameters: Ae_u (0-t); Single dose:PK parameters: Rate_u (max); Single dose:PK parameters:Fe_u (0-t); Multiple administration: PK parameters:Cmax,ss; Multiple administration: PK parameters:Tmax,ss; Multipl...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov